To appraise the clinical and cost effectiveness of cemiplimab within its marketing authorisation for treating cutaneous squamous cell carcinoma.
Status In progress
Process STA 2018
ID number 1367

Provisional Schedule

Expected publication 03 July 2019

Project Team

Project lead Thomas Feist

Email enquiries


Companies sponsors Regeneron Pharmaceuticals and Sanofi (cemiplimab)
Others Department for Health and Social Care
  NHS England
  Welsh Government
Professional groups Association of Cancer Physicians
  British Association of Dermatologists
  British Association of Skin Cancer Specialist Nurses
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists


General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research
  National Cancer Research Institute


Key events during the development of the guidance:

Date Update
13 June 2019 Committee meeting: 2
09 April 2019 Committee meeting: 1
24 August 2018 Invitation to participate
30 April 2018 (13:00) Scoping workshop (London)
01 March 2018 - 29 March 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
05 March 2018 In progress, Ref from DH received 05.12.17
05 December 2017 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance